BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34263696)

  • 1. Glofitamab CD20-TCB bispecific antibody.
    Minson A; Dickinson M
    Leuk Lymphoma; 2021 Dec; 62(13):3098-3108. PubMed ID: 34263696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
    Sam J; Hofer T; Kuettel C; Claus C; Thom J; Herter S; Georges G; Korfi K; Lechmann M; Eigenmann MJ; Marbach D; Jamois C; Lechner K; Krishnan SM; Gaillard B; Marinho J; Kronenberg S; Kunz L; Wilson S; Briner S; Gebhardt S; Varol A; Appelt B; Nicolini V; Speziale D; Bez M; Bommer E; Eckmann J; Hage C; Limani F; Jenni S; Schoenle A; Le Clech M; Vallier JP; Colombetti S; Bacac M; Gasser S; Klein C; Umaña P
    Blood; 2024 May; 143(21):2152-2165. PubMed ID: 38437725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
    Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M
    PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
    Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M
    Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
    Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
    J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
    Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
    Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
    Stanglmaier M; Faltin M; Ruf P; Bodenhausen A; Schröder P; Lindhofer H
    Int J Cancer; 2008 Sep; 123(5):1181-9. PubMed ID: 18546289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.
    Xiong D; Xu Y; Liu H; Peng H; Shao X; Lai Z; Fan D; Yang M; Han J; Xie Y; Yang C; Zhu Z
    Cancer Lett; 2002 Mar; 177(1):29-39. PubMed ID: 11809528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.
    Wang C; Liu Y
    J Hematol Oncol; 2023 Mar; 16(1):20. PubMed ID: 36895020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
    Bacac M; Colombetti S; Herter S; Sam J; Perro M; Chen S; Bianchi R; Richard M; Schoenle A; Nicolini V; Diggelmann S; Limani F; Schlenker R; Hüsser T; Richter W; Bray-French K; Hinton H; Giusti AM; Freimoser-Grundschober A; Lariviere L; Neumann C; Klein C; Umaña P
    Clin Cancer Res; 2018 Oct; 24(19):4785-4797. PubMed ID: 29716920
    [No Abstract]   [Full Text] [Related]  

  • 19. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Hsu YT; Wu SJ; Kao HW; Hsiao SY; Liao CK; Chen TY; Wang MC
    Cancer; 2024 Jun; 130(11):1972-1981. PubMed ID: 38306242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.